Protein Mediated Protection from Microbial Keratitis
Protein Mediated Protection from Microbial Keratitis
批准号:
6736542
负责人:
Mitchell C. Sanders
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-06-01 至 2005-05-31
中文摘要
描述(由申请人提供):微生物性角膜炎是一种严重的眼部感染,可通过角膜瘢痕或穿孔导致永久性视力丧失。铜绿假单胞菌是最常见的眼部分离株之一,并且已被证明与75%的接触透镜介导的感染性角膜炎相关。接触透镜配戴者更容易发生微生物性角膜炎,新疗法的开发是一个重要的研究领域。目前的做法是用抗生素治疗感染,但最近出现的耐药菌株增加了对替代治疗的需求。虽然导致微生物角膜炎的事件的确切顺序尚未完全阐明,但宿主和微生物蛋白酶在角膜炎中的作用已得到充分记载。本申请提出使用新型“保护蛋白”介导的技术作为对抗角膜炎的替代方案。“保护蛋白”是具有两类不同活性的新型分子。第一个明显的活性是通过重折叠稳定蛋白质,而第二个不太明显但同样令人印象深刻的Protector蛋白质组属于蛋白酶抑制剂类。
我们的假设是,ECI表征的“保护蛋白”; α A-晶体蛋白、γ D-晶体蛋白和嵌合蛋白,胃酶抑素/亮抑酶肽/α A-晶体蛋白将抑制由宿主和病原体分泌的蛋白水解酶,从而作为针对微生物角膜炎的管理的良好治疗剂。SBIR资助的第一阶段的具体目标是基于这一前提,并将为我们提供重要的体外生化分析,从而为更有说服力的体内动物模型研究提供途径。
我们设想将这些“Protector蛋白”附着到长期配戴的软性接触镜上将显著降低与接触透镜配戴者相关的微生物角膜炎的发病率,并且可以吸引该市场的显著部分。总之,本申请提出使用新型“保护蛋白”介导的技术作为对抗角膜炎的替代方案。
英文摘要
DESCRIPTION (provided by applicant): Microbial keratitis is a serious eye infection that can lead to permanent vision loss through corneal scarring or perforation. Pseudomonas aeruginosa is one of the most frequent ocular isolates and has been shown to be associated with 75% of contact lens mediated infectious keratitis. Contact lens wearers are more prone to microbial keratitis and the development of new therapies is an important field of research. The current practice is to treat the infection with antibiotics, but the recent emergence of resistant bacterial strains has heightened the need for alternative treatments. Although the exact sequence of events leading to microbial keratitis has not been fully elucidated, the role of the host and microbial proteases in keratitis has been well documented. This application proposes the use of a novel "Protector protein" mediated technology as an alternative regimen for combating keratitis. "Protector proteins" are novel molecules that have two distinct classes of activities. The first obvious activity is protein stabilization via refolding while the second less obvious but equally impressive group of Protector proteins, belong to the class of protease inhibitors.
Our hypothesis is that ECI characterized "Protector proteins"; alphaA-Crystallin, gammaD-Crystallin and the chimeric protein, pepstatin/leupeptin/alphaA-Crystallin will inhibit the proteolytic enzymes secreted by the host and the pathogen, thus serving as a good therapeutic agent against the management of microbial keratitis. The specific aims designed for phase I of SBIR grant, are based on this premise and will provide us with significant in vitro biochemical analysis leading way to more telling in vivo animal model studies.
We envisage that attachment of these "Protector proteins" onto extended wear soft contact lenses would significantly reduce the incidence of microbial keratitis associated with contact lens wearers and could attract significant portion of this market. In summary, this application proposes the use of a novel "Protector protein" mediated technology as an alternative regimen for combating keratitis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Rapid Detection of Periprosthetic Joint Infection
-
批准号:8314605
-
项目类别:
-
资助金额:$29.83万
-
财政年份:2012
-
负责人:Mitchell C. Sanders
-
依托单位:
Simple and Inexpensive Diagnostic Tools for Yeast Infections
-
批准号:7482629
-
项目类别:
-
资助金额:$20.09万
-
财政年份:2008
-
负责人:Mitchell C. Sanders
-
依托单位:
Diagnostic Tool for the Point-of-Care Detection of Infection in Chronic Wounds
-
批准号:7666928
-
项目类别:
-
资助金额:$51.15万
-
财政年份:2007
-
负责人:Mitchell C. Sanders
-
依托单位:
COMMERCIAL POTENTIAL FOR P26 IN VITRO AND IN VIVO
-
批准号:2868071
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1999
-
负责人:Mitchell C. Sanders
-
依托单位: